EDITAS MEDICINE, INC. Investment Income, Net, Amortization of Discount and Premium
EDITAS MEDICINE, INC. (EDIT) reported Investment Income, Net, Amortization of Discount and Premium of $142.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium · last filed 2026-08-05
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for the quarter ending 2026-06-30 was $142.00K, a 44.75% decline year-over-year.
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for the quarter ending 2025-09-30 was $62.00K, a 95.32% decline year-over-year.
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for fiscal 2025 was $902.00K, a 84.42% decline from fiscal 2024.
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for fiscal 2024 was $5.79M, a 20.07% increase from fiscal 2023.
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for fiscal 2023 was $4.82M, a 566.16% increase from fiscal 2022.
- EDITAS MEDICINE, INC. investment income, net, amortization of discount and premium for fiscal 2022 was $724.00K.
| Period end | Investment Income, Net, Amortization of Discount and Premium 3 month | Investment Income, Net, Amortization of Discount and Premium 6 month | Investment Income, Net, Amortization of Discount and Premium 9 month | Investment Income, Net, Amortization of Discount and Premium 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $142.00K 10-Q · filed 2026-08-05 | $142.00K derived: sum of 3 quarters · filed 2026-08-05 | $204.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $62.00K derived: sum of 3 quarters · filed 2026-05-05 | $319.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $62.00K derived: sum of 2 quarters · filed 2026-03-09 | $319.00K derived: sum of 3 quarters · filed 2026-08-05 | $902.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $319.00K derived: sum of 2 quarters · filed 2026-08-05 | $902.00K 10-Q · filed 2025-11-10 | $1.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $840.00K 10-Q · filed 2026-08-05 | $1.71M derived: sum of 3 quarters · filed 2026-08-05 | $3.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $583.00K 10-Q · filed 2026-05-05 | $1.45M derived: sum of 2 quarters · filed 2026-05-05 | $2.78M derived: sum of 3 quarters · filed 2026-05-05 | $4.66M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $869.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.19M derived: sum of 2 quarters · filed 2026-03-09 | $4.08M derived: sum of 3 quarters · filed 2026-03-09 | $5.79M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.21M derived: sum of 2 quarters · filed 2025-11-10 | $4.92M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.60M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $1.72M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $4.82M 10-K · filed 2025-03-05 | |||
| 2022-12-31 | $724.00K 10-K · filed 2025-03-05 | |||
| 2021-12-31 | -$1.66M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |